Clinical and epidemiological features of myasthenia gravis in a single tertiary neuromuscular center
Abstract
Background: Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating skeletal muscle weakness and fatigability due to impaired neuromuscular transmission. Its clinical expression is heterogeneous. The epidemiology, age at onset, patterns of clinical involvement, and disease trajectory vary across populations. Despite these variations, data from large, well-characterized cohorts in middle-income settings remain scarce, particularly from Latin America. Improved characterization of MG in these contexts is essential to better understand its clinical spectrum and to inform diagnostic and management strategies in real-world practice. Objective: To describe the epidemiological profile and clinical spectrum of myasthenia gravis in patients followed at a tertiary neuromuscular reference centre. Methods: Patients with confirmed MG followed at the Hospital das Clínicas de Ribeirão Preto (HCFMRP-USP) between 2000 and 2025 were included. MG was defined by fluctuating weakness and at least one of the following (1) a decrement in CMAP amplitude greater than 10% in at least two muscle groups on repetitive nerve stimulation; (2) presence of anti–acetylcholine receptor (AChR) or anti–muscle-specific kinase (MuSK) antibodies; or (3) abnormal single-fibre electromyography. Clinical features, clinical progression over time, demographic information, neurophysiological and laboratory data were retrospective collected from medical records using a predefined proforma. Results: Four hundred nineteen patients were included. The mean age at onset was 40,8 years 40.8 ± 20.7 years (range 1–89); and 60.1% were female, 82% were self-declared Caucasian, and 75 had associated autoimmune diseases. Generalized onset occurred in 42% (n 176), ocular in 38.9% (n 163), and bulbar in 18.9% (n 79). Early-onset MG was most frequent (50.6%), followed by very-late onset (17.4%), late onset (17.2%), and juvenile (14.8%). Female sex was associated with early-onset disease (χ²=9.83, p=0.0017; OR 1.88). Thirty-seven patients had thymoma (mean age 42.9 ± 13.9, range 15–71); 70.2% were AChR-positive. Three cases of immune checkpoint inhibitor–associated MG were identified. Serology was available for 278 patients: 86.0% AChR-positive, 5.4% MuSK-positive, 8.3% double seronegative, and 0.4% double seropositive, without association between sex and antibody status. Among ocular cases, 110 later generalized with a mean time to 3,3 years (median 1.0 year, IQR 0.08–3.0). At last follow-up, 32% had MGFA >2A, suggesting poor disease control. Antibody status was not associated with disease severity. Conclusion: In this large real-world cohort, MG showed substantial clinical heterogeneity, with frequent non-generalized onset and significant progression over time. Despite available therapies, a considerable proportion of patients remained with moderate to severe disease, highlighting persistent gaps in disease control. Antibody status did not predict severity, underscoring the need for better clinical stratification and management strategies.